K2 Principal Fund, L.P. Silverback Therapeutics, Inc. Call Options Transaction History

K2 Principal Fund, L.P.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	N/A	-38,100 Reduced 26.48%	105,800 $0
Q2 2024 Aug 14, 2024	SELL	N/A	-27,300 Reduced 15.95%	143,900 $0
Q1 2024 May 14, 2024	SELL	N/A	-471,900 Reduced 73.38%	171,200 $0
Q4 2023 Feb 14, 2024	SELL	N/A	-45,800 Reduced 6.65%	643,100 $0
Q3 2023 Nov 13, 2023	SELL	N/A	-11,000 Reduced 1.57%	688,900 $0
Q2 2023 Aug 14, 2023	BUY	N/A	682,100 Added 3832.02%	699,900 $0
Q1 2023 May 11, 2023	BUY	N/A	17,800 New	17,800 $0

163

62.7M

872K

589K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.